Literature DB >> 8388556

HLA antigens, Lewis antigens, and blood groups in patients with testicular germ-cell tumors.

K P Dieckmann1, R Klän, S Bünte.   

Abstract

Clinical observations, epidemiologic data, and results of animal experiments support the theory of genetic anticipation of testicular germ-cell tumors. Attempts to find genetic markers of testicular cancer have yielded conflicting results. We studied blood groups of 577 patients treated for testicular germ-cell tumor (GCT) and controls. Lewis antigens of 143 patients treated for testicular GCT, and controls, and HLA antigens of 215 patients treated for testicular GCT and controls. Blood-group frequencies were the same in patients and controls. Lewis antigen Le(a-b-) was more frequent in patients than in controls (p = 0.046; RR = 2.38). HLA Bw41 was associated with seminoma (p = 0.0001; RR = 8.2). None of the previously reported associations of other HLA antigens with GCT was confirmed. We found no association of HLA antigens with susceptibility to metastatic disease. The associations of Le(a-b-) with testicular GCT and of HLA Bw41 with seminoma support the contention that genetic factors are involved in the etiology and pathogenesis of GCT. HLA-Bw41 could possibly be employed as a risk marker for seminoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388556     DOI: 10.1159/000227190

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Genetic anticipation and musculoskeletal disease.

Authors:  C M Deighton; G Thomson
Journal:  Ann Rheum Dis       Date:  1994-12       Impact factor: 19.103

Review 2.  Genetic factors in malignant germ-cell tumors.

Authors:  K Heimdal; S D Fosså
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

3.  Management of contralateral testicular intraepithelial neoplasia in patients with testicular germ-cell tumor.

Authors:  K P Dieckmann; V Loy
Journal:  World J Urol       Date:  1994       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.